Roadmap
Программа Nightbox NKG2D-LIF6 + federal pipeline + supporting pillars. Honest milestones, не aspirational claims.
Completed
Q1 2026
In silico characterization NKG2D-LIF6 chimera
~99% TGI ceiling на CRC syngeneic models. AlphaFold structural validation + Rosetta refinement.Q1 2026
Freedom-to-operate scan
USPTO + EPO + WIPO PatentScope. Clean IP whitespace на NKG2D-LIF6 chimera.Q2 2026 — май
Liaison Framework v2.3 + Market Re-Entry Roadmap v1.0
Editorial doctrine для US↔РФ bilateral сотрудничества. Commerce companion с 14+ company analysis.Q2 2026 — 17 мая
CAGE Code 20BA7 assigned
DLA Battle Creek. SAM.gov Active. DLA case INC-GSAFSD21007772 resolved.Q2 2026 — 19 мая
DSIP firm registered + eRA Commons institution submitted
Federal SBIR pipeline разблокирован.In progress
Q2 2026
Provisional patent filing
Specific NKG2D-LIF6 chimera. Через qualified patent counsel.06/24/2026
USAF SBIR DAF26BX02-NV501 submission
Voice-Enabled AI Assistant для Austere Environments. SilverDuck + UniGPU match. $150-250K Phase I.09/05/2026
NIH NCI SBIR Omnibus PA-26-273 submission
$300-400K Phase I. NKG2D-LIF6 gene therapy oncology.Planned
Q3-Q4 2026
Construct synthesis + HEK293 in vitro expression
Smoke test перед in vivo.Q3 2026
AAV9 packaging at academic vector core / CDMO partner
Research-grade lot для preclinical studies.Q3-Q4 2026
In vivo validation в 3 syngeneic murine models
CRC, melanoma, pancreatic. Qualified CRO partner.H2 2026
Pre-IND meeting с FDA CBER
Briefing book + agency feedback на IND-enabling tox.Q3 2026
Pre-seed round ($3M-$5M target)
Use of proceeds: in vivo validation (60%), wet-lab hire (20%), pre-IND prep (15%), regulatory (5%).2027
IND-enabling toxicology (GLP, 6-12 months)
External CRO. Standard FDA submission requirement.2027-2028
IND filing + Phase 1 first-in-human
Subject to in vivo + tox completion. FDA review timeline.